Department of Urology, University of Michigan, Ann Arbor, 48109, USA.
Curr Urol Rep. 2011 Feb;12(1):18-23. doi: 10.1007/s11934-010-0149-x.
The use of percutaneous renal mass biopsy (RMB) has increased in recent years, likely in parallel with the growing incidence of renal cell carcinoma and small renal masses in particular. Biopsy and imaging techniques are improving, and diagnostic sufficiency and accuracy of RMB now are much higher in large-volume, experienced centers. Overall morbidity is low. This has led to a significant expansion of the indications for biopsy beyond documenting renal involvement for patients with metastatic disease or other systemic illnesses. While there still are limitations to its use and clinical judgment is paramount, RMB is proving to be a valuable tool in the clinical diagnosis and management of small renal masses.
近年来，经皮肾肿瘤活检（RMB）的应用有所增加，可能与肾细胞癌发病率的上升以及特别是小肾肿瘤的增加有关。活检和成像技术在不断改进，在大容量、有经验的中心，RMB 的诊断充分性和准确性现在要高得多。总的发病率很低。这导致活检的适应证显著扩大，不仅限于为患有转移性疾病或其他全身性疾病的患者记录肾脏受累情况。虽然它的使用仍然存在局限性，临床判断至关重要，但 RMB 已被证明是小肾肿瘤临床诊断和治疗的有用工具。
